Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
UPDATE: Cantor Fitzgerald Maintains GW Pharma (GWPH) at Overweight, Lowers PT to $211
-
GW Pharma (GWPH) PT Raised to Street High $235 at Cantor Fitzgerald
-
UPDATE: GW Pharma (GWPH) PT Raised to Street High $205 at Cantor Fitzgerald
-
Cantor Remains Positive on GW Pharma (GWPH), 'Smooth Sailing Approaching Epidiolex AdCom'
-
GW Pharma (GWPH) PT Lowered to $192 at Cantor Fitzgerald
-
GW Pharma (GWPH) Plenty of Room for Multiple AEDs - Cantor Fitzgerald
-
GW Pharma (GWPH): Nearing Completion of Rolling NDA - Cantor
-
Streetinsider.com's Hot Lunchtime Reads 12/5: (AZN) (LPLA) (GWPH) (CRUS)
-
GW Pharma (GWPH) PT Raised to $208 at Cantor Fitzgerald; In Good Shape for 1st-Half 2017 NDA Submission
-
GW Pharma (GWPH) PT Raised to $182 at Cantor Fitzgerald Following Successful Second LGS Trial
-
Cantor Fitzgerald Sees Potential GW Pharma (GWPH) Takeout Price Around $165/Share
-
Cantor Fitzgerald Starts GW Pharma (GWPH) at Buy
-
Pre-Open Stock Movers 6/17: (ANFI) (FST) (GWPH) Higher; (PGEM) (KONA) (KND) Lower (more...)

